Author

T. Budak-Alpdogan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

K. Gowda· 1 shared M. K. Pandey· 1 shared O. S. F. Al Odat· 1 shared S. C. Jonnalagadda· 1 shared S. G. Amin· 1 shared S. K. Srivastava· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

K. Gowda

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A new efficacious Mcl-1 inhibitor maximizes bortezomib and venetoclax responsiveness in resistant multiple myeloma cells

O. S. F. Al Odat, K. Gowda, S. K. Srivastava, S. G. Amin, S. C. Jonnalagadda, T. Budak-Alpdogan, M. K. Pandey

This paper identifies KS18, a Mcl-1 inhibitor, as a potential treatment for multiple myeloma, showing it enhances apoptosis and overcomes resistance to bortezomib and venetoclax in resistant cells and mouse models.

bioRxiv · Dec 6, 2023 · PreprintPharmacology & Toxicology